Uloric (febuxostat)

Override(s)	Approval Duration
Prior Authorization	1 year
Quantity Limit	

Medications	Quantity Limit
Uloric (febuxostat)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Uloric (febuxostat) may be approved if the following criteria are met:

- I. Individual has had a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to generic allopurinol; **OR**
- II. Individual has a contraindication to use of allopurinol.

Requests for **brand** Uloric must also meet the following criteria, in addition to the above Prior Authorization criteria:

I. Individual has failed an adequate trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of one chemically equivalent generic febuxostat agent;

AND

- A. Generic febuxostat had inadequate response; OR
- B. Generic febuxostat caused adverse outcome; OR
- C. The individual has a genuine allergic reaction to an inactive ingredient in generic agent. Allergic reaction(s) must be clearly documented in the individual's medical record.

Key References:

- 1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: April 12, 2022.
- 2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- 3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Rheumatol.* 2020;72(6):879-895. Available at: https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.41247.
- 4. Lexi-Comp ONLINE[™] with AHFS[™], Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.